Nephrotoxicity in a Patient Treated with Pemetrexed

Indian Journal of Nephrology | Volume 27 | Issue 3 | May-June 2017 243 Sir, Pemetrexed is an antifolate agent approved for the treatment of non‐small cell lung cancer. A 62 year old male was admitted to our hospital in December 2014. He was diagnosed with metastatic non‐small cell lung cancer. He was treated with first‐line chemotherapy, including paclitaxel infusions and carboplatin, every 3 weeks for four cycles; the disease had partially responded with good tolerance. That is why a maintenance monotherapy by pemetrexed was administered at a dose of 500 mg/m2 (900 mg) every 3 weeks, together with folic acid supplements for a total of 3 cycles. Serum creatinine before pemetrexed administration was 0.8 mg/dl. It progressively increased to 2.4 mg/dl, and he developed anemia (hemoglobin was 9.7 g/dl) after third cycle infusion of pemetrexed. Pemetrexed was stopped, and the patient was referred to a nephrologist. On presentation, blood pressure was 140/80 mmHg, and physical examination was unremarkable. He appeared euvolemic clinically. Serum creatinine level was 2.2 mg/dl. A 24 h urine collection revealed a 0.7 g proteinuria without hematuria, glycosuria, leukocyturia, or proximal tubular dysfunction. Serum electrolyte levels and renal ultrasound were both normal. The patient underwent kidney biopsy. Light microscopy examination revealed ten glomeruli, three of those showed global sclerosis, and the remaining were normal. The interstitial tissue had focal edema with moderate infiltration with mononuclear inflammatory cells and fibrosis in approximately 40% of the cortex with moderate tubular atrophy and acute tubular injury. Artery walls are thickened by intimal fibrosis. The immunofluorescent examination showed negative expression of immunoglobulins IgG, IgA, IgM, complement fragments C3, C1q, and k, l light chains in glomeruli, tubules, and vessels. Electron microscopy examination was not performed [Figure 1]. The patient’s serum creatinine level remained elevated, but stable, 5 months after discontinuation of pemetrexed treatment. Cases of renal impairment have been reported after pemetrexed treatment, usually accompanied by significant myelosuppression that reversed after discontinuation of the drug. Our patient developed irreversible kidney injury related to interstitial fibrosis and acute tubular necrosis following treatment with pemetrexed for metastatic non‐small cell lung cancer. Acute tubular necrosis seemed to be of nephrotoxic origin as there were no signs of prolonged significant renal hypoperfusion. Interstitial fibrosis was attributed to pemetrexed. Although our patient had previously received paclitaxel and carboplatin, acute renal failure appeared only after pemetrexed treatment. Nephrotoxicity in a Patient Treated with Pemetrexed